Review
doi: 10.1161/CIR.0000000000000394.
Epub 2016 Mar 28.
Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association
- PMID: 27022063
- DOI: 10.1161/CIR.0000000000000394
Item in Clipboard
Review
Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association
Circulation.
.
No abstract available
Keywords: AHA Scientific Statements; implantable cardioverter-defibrillator; sudden cardiac death; ventricular fibrillation; ventricular tachycardia; wearable cardioverter-defibrillator.
Similar articles
-
Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Eur Heart J. 2013 Aug;34(29):2230-42. doi: 10.1093/eurheartj/eht167. Epub 2013 May 31. Eur Heart J. 2013. PMID: 23729691 Review.
-
Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.Arch Intern Med. 2009 Sep 14;169(16):1500-6. doi: 10.1001/archinternmed.2009.255. Arch Intern Med. 2009. PMID: 19752408
-
The role of the wearable cardioverter defibrillator in clinical practice.Cardiol Clin. 2014 May;32(2):253-70. doi: 10.1016/j.ccl.2013.11.002. Cardiol Clin. 2014. PMID: 24793801 Review.
-
Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator.Pacing Clin Electrophysiol. 2014 May;37(5):562-8. doi: 10.1111/pace.12319. Epub 2013 Dec 3. Pacing Clin Electrophysiol. 2014. PMID: 24762055
-
Sudden cardiac death in dialysis: do current guidelines for implantable cardioverter defibrillator therapy apply to patients with end-stage kidney disease?Semin Dial. 2012 May;25(3):272-6. doi: 10.1111/j.1525-139X.2012.01067.x. Epub 2012 Mar 27. Semin Dial. 2012. PMID: 22452711
Cited by
-
Extreme Risk of Sudden Cardiac Death within Three Months after Revascularization in Patients with Ischemic Left Ventricular Systolic Dysfunction.Rev Cardiovasc Med. 2023 Oct 18;24(10):294. doi: 10.31083/j.rcm2410294. eCollection 2023 Oct. Rev Cardiovasc Med. 2023. PMID: 39077580 Free PMC article.
-
No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry.Front Cardiovasc Med. 2024 Jul 10;11:1384736. doi: 10.3389/fcvm.2024.1384736. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39049954 Free PMC article.
-
First human safety and effectiveness study of defibrillation with a novel patch wearable cardioverter-defibrillator.Europace. 2024 Jul 2;26(7):euae189. doi: 10.1093/europace/euae189. Europace. 2024. PMID: 39001864 Free PMC article.
-
Expanded application of wearable cardioverter defibrillators beyond current guidelines: proposal for a European register explained through single clinical scenarios.Open Heart. 2024 Mar 8;11(1):e002597. doi: 10.1136/openhrt-2023-002597. Open Heart. 2024. PMID: 38458770 Free PMC article.
-
Wearable Cardioverter Defibrillator Shortens the Lengths of Stay in Patients with Left Ventricular Dysfunction after Myocardial Infarction: A Single-Centre Real-World Experience.J Clin Med. 2023 Jul 25;12(15):4884. doi: 10.3390/jcm12154884. J Clin Med. 2023. PMID: 37568286 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
